Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Jul 20;10:1173–1187. doi: 10.2147/CIA.S86493

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2015 Lin et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License

The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

Life span, body weight, and motor ability of R6/2 HD mice and their WT under oral B307 and sham treatments.

Notes: (A) Survival durations of R6/2 HD mice were shorter than their WT but were increased under oral B307 treatment. (B) Body weight of R6/2 HD mice was significantly reduced as compared to their WT from 10 weeks of age and thereafter, while it had significantly increased under oral B307 from 10 weeks of age and thereafter. Furthermore, brain (cerebrum plus cerebellum) weight in the R6/2 HD mice had been significantly reduced as compared to their WT from 10 weeks of age and thereafter, while it had significantly increased under oral B307 from 10 weeks of age and thereafter. There were six mice per each group. (C) Latencies to fall in the R6/2 HD mice identified by rotarod testing were significantly lower than their WT from 10 weeks of age and thereafter, while they were significantly increased under oral B307 from 10 weeks of age and thereafter. There were six mice per each group. (D) Heart weight in R6/2 HD mice had been significantly reduced as compared to their WT (N=6) from 10 weeks of age and thereafter, while they were significantly increased under oral B307 from 10 weeks of age and thereafter. There were six mice per each group. Both H&E staining and IHC staining of mHtt aggregation were illustrated in the plot. Expressions of myocarditis (marked by arrows in H&E staining) and mHtt aggregation (marked by arrows in IHC staining) were remarkable in comparison to their WT but were reduced under oral B307 treatment. Values are mean ± SEM (**P<0.01, *P<0.05, two-way ANOVA followed by a Student–Newman–Keuls multiple comparisons posttest).

Abbreviations: WT, wild-type littermate controls; HD, Huntington’s disease; H&E, hematoxylin and eosin; mHtt, mutant huntingtin; IHC, immunohistochemical; SEM, standard error of the mean; ANOVA, analysis of variance.

Life span, body weight, and motor ability of R6/2 HD mice and their WT under oral B307 and sham treatments.

Notes: (A) Survival durations of R6/2 HD mice were shorter than their WT but were increased under oral B307 treatment. (B) Body weight of R6/2 HD mice was significantly reduced as compared to their WT from 10 weeks of age and thereafter, while it had significantly increased under oral B307 from 10 weeks of age and thereafter. Furthermore, brain (cerebrum plus cerebellum) weight in the R6/2 HD mice had been significantly reduced as compared to their WT from 10 weeks of age and thereafter, while it had significantly increased under oral B307 from 10 weeks of age and thereafter. There were six mice per each group. (C) Latencies to fall in the R6/2 HD mice identified by rotarod testing were significantly lower than their WT from 10 weeks of age and thereafter, while they were significantly increased under oral B307 from 10 weeks of age and thereafter. There were six mice per each group. (D) Heart weight in R6/2 HD mice had been significantly reduced as compared to their WT (N=6) from 10 weeks of age and thereafter, while they were significantly increased under oral B307 from 10 weeks of age and thereafter. There were six mice per each group. Both H&E staining and IHC staining of mHtt aggregation were illustrated in the plot. Expressions of myocarditis (marked by arrows in H&E staining) and mHtt aggregation (marked by arrows in IHC staining) were remarkable in comparison to their WT but were reduced under oral B307 treatment. Values are mean ± SEM (**P<0.01, *P<0.05, two-way ANOVA followed by a Student–Newman–Keuls multiple comparisons posttest).

Abbreviations: WT, wild-type littermate controls; HD, Huntington’s disease; H&E, hematoxylin and eosin; mHtt, mutant huntingtin; IHC, immunohistochemical; SEM, standard error of the mean; ANOVA, analysis of variance.